Anesthetic Effect - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anesthetic Effect - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Anesthetic Effect - Pipeline Review, H2 2016', provides an overview of the Anesthetic Effect pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
- The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects
- The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Anesthetic Effect

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anesthetic Effect Overview 9
Therapeutics Development 10
Pipeline Products for Anesthetic Effect - Overview 10
Pipeline Products for Anesthetic Effect - Comparative Analysis 11
Anesthetic Effect - Therapeutics under Development by Companies 12
Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 14
Anesthetic Effect - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anesthetic Effect - Products under Development by Companies 19
Anesthetic Effect - Products under Investigation by Universities/Institutes 20
Anesthetic Effect - Companies Involved in Therapeutics Development 21
Biolab Farmaceutica Ltda 21
Drawbridge Pharmaceuticals Pty Ltd 22
Expanesthetics Inc 23
Jiangsu Hengrui Medicine Co., Ltd. 24
Lipicard Technologies Limited 25
NanoMedex Pharmaceuticals, Inc. 26
Paion AG 27
Phosphagenics Limited 28
Physica Pharma 29
Primex Pharmaceuticals Oy 30
Proteus SA 31
Sphaera Pharma Pvt. Ltd. 32
Taiwan Liposome Company, Ltd. 33
The Medicines Company 34
Anesthetic Effect - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 43
ABP-700 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ADV-6209 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
alphaxalone - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
bupivacaine hydrochloride - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Carboetomidate - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
gabafol - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
HSK-3486 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
LT-1121 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
LT-1123 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Methoxycarbonyl Carboetomidate - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Methoxycarbonyl Etomidate - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
neosaxitoxin - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
PB-5109 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
PHY-301 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
propofol - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
propofol - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
propofol microemulsion - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
remimazolam - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
remimazolam - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecule for General Anesthetic Effect - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules for General Anesthetic Effect - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
SPR-819 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Anesthetic Effect - Dormant Projects 75
Anesthetic Effect - Discontinued Products 77
Anesthetic Effect - Product Development Milestones 78
Featured News & Press Releases 78
Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China 78
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy 78
Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA 79
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment 80
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy 80
Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings 81
Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting 82
Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 83
Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia 83
Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy 84
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 85
Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion 85
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 86
Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014 86
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 86
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Anesthetic Effect, H2 2016 10
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2016 21
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2016 22
Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2016 23
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 24
Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H2 2016 25
Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2016 26
Anesthetic Effect - Pipeline by Paion AG, H2 2016 27
Anesthetic Effect - Pipeline by Phosphagenics Limited, H2 2016 28
Anesthetic Effect - Pipeline by Physica Pharma, H2 2016 29
Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H2 2016 30
Anesthetic Effect - Pipeline by Proteus SA, H2 2016 31
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 32
Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 33
Anesthetic Effect - Pipeline by The Medicines Company, H2 2016 34
Assessment by Monotherapy Products, H2 2016 35
Number of Products by Stage and Target, H2 2016 37
Number of Products by Stage and Mechanism of Action, H2 2016 39
Number of Products by Stage and Route of Administration, H2 2016 41
Number of Products by Stage and Molecule Type, H2 2016 42
Anesthetic Effect - Dormant Projects, H2 2016 75
Anesthetic Effect - Dormant Projects (Contd..1), H2 2016 76
Anesthetic Effect - Discontinued Products, H2 2016 77